【摘要】 目的基于文献数据,评价脑心通胶囊治疗心绞痛、脑梗死和血管性痴呆成本-效果。方法检索2000年1月1日~2015年9月7日国内外中英文数据库,收集脑心通胶囊治疗冠心病心绞痛、脑梗死和血管性痴呆的随机对照试验文献,采用Revman5.0软件对符合纳排标准的研究进行统计分析,对各病症的主要结局指标进行药物经济学评价。结果共纳入研究39个,其中冠心病10篇,脑梗塞14篇,血管性痴呆15篇。Meta分析结果显示:1在脑心通胶囊治疗心绞痛疗效中与对照组,中药对照组及复方丹参片比较具有统计学意义(P<0.05);在心电图疗效中与对照药比较无统计学意义(P=0.11),与中药治疗组(P=0.002)和复方丹参片(P=0.05)比较具有统计学意义;在安全性分析中与对照药比较无统计学意义(P=0.79)。2在脑心通胶囊治疗脑梗塞的临床疗效中无统计学意义(P=0.09),与中药治疗组比较具有统计学意义(P=0.03)。3在脑心通胶囊治疗血管性痴呆的临床疗效、MMSE量表评分、在ADL量表评分、血浆粘度等血液流变学指标中与对照药比较具有统计学意义(P<0.05)。药物经济学分析结果显示:脑心通胶囊在治疗冠心病心绞痛、脑梗死中,其经济性均优于通心络胶囊,次于复方丹参片和地奥心血康胶囊。通过与复方丹参片的增量成本-效果分析发现,在心绞痛疗效方面,脑心通胶囊每增加1个疗效,多花费6.4元,在心电图疗效方面,脑心通胶囊每增加1个疗效,多花8.01元;脑心通胶囊在治疗血管性痴呆病症中,其经济性优于都可喜片。结论脑心通胶囊在冠心病心绞痛、脑梗死、血管性痴呆的治疗中具有良好的临床效果和经济性。更多还原

【Abstract】 Objective To evaluate the cost-effectiveness of Naoxintong Capsule in angina, cerebral infarction, and vascular dementia. Methods Randomized controlled trials(RCTs) published in Chinese or English from 2000.1.1 to 2015.9.7 of angina, cerebral infarction, and vascular dementia were collected from literature databases. Statistical analysis was conducted by Rev Man 5.0. Pharmacoeconomic evaluation was completed for main outcome indicators. Result 39 RCTs were enrolled in the study, in which 10 for angina, 14 for cerebral infarction and 15 for vascular dementia. The results of meta-analysis showed that: 1with respect to angina, the efficacy between control group, Chinese medicine group and Danshen group with Naoxintong group was statistically significant(P<0.05); with respect to efficacy on electrocardiogram(ECG), no difference was observed between control group and Naoxintong group(P=0.11); statistical difference was observed between Chinese medicine group(P=0.002) and Danshen group(P=0.05) with Naoxintong group; no difference was observed between control group and Naoxintong group in safety analysis(P=0.79). 2with respect to cerebral infarction, no difference was observed(P=0.09) in clinical efficacy, expect compared with Chinese medicine group(P=0.03). 3with respect to vascular dementia, statistical difference was observed between control group and Naoxintong group in clinical curative effect, MMSE scale score, ADL scale score(P<0.05). The results of pharmacoeconomic analysis showed that: with respect to economic efficiency of treatment of angina and cerebral infarction, Naoxintong capsule is better than Tongxinluo, but inferior to Danshen and Di Ao Xinxuekang Capsule. Using Naoxintong capsule, each additional one effect of angina will cost 6.4 yuan; each additional one effect of ECG will cost 8.01 yuan; with respect to economic efficiency of treatment of vascular dementia, Naoxintong capsule is better than Duxil. Conclusion On treatment of angina, cerebral infarction, vascular dementia, Naoxintong Capsule has good clinical effect and cost-effectiveness.更多还原